OverviewChartNewsTraderScreen

L&S Knock-Out Axsome Therapeutics.../  DE000LX4AAT9  /

Lang & Schwarz
2024-11-12  10:59:51 PM Chg.+0.76 Bid10:59:51 PM Ask10:59:51 PM Underlying Strike price Expiration date Option type
3.14EUR +31.93% 3.14
Bid Size: -		 3.44
Ask Size: -		 - 63.8334 EUR 2078-12-31 Call
GlobeNewswire 08-27 Axsome Therapeutics to Participate in Investor Conferences in September
GlobeNewswire 08-21 Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sando...
GlobeNewswire 08-05 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 07-11 Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
GlobeNewswire 06-05 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
GlobeNewswire 06-04 Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During...
GlobeNewswire 06-03 Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
GlobeNewswire 05-30 Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire 05-29 Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function ...
GlobeNewswire 05-28 Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Ps...
GlobeNewswire 05-08 Axsome Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire 05-06 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 05-01 Axsome Therapeutics Recognizes May as Mental Health Awareness Month
GlobeNewswire 04-15 Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurolog...
GlobeNewswire 04-10 Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
GlobeNewswire 04-01 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating...
GlobeNewswire 03-25 Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Nee...
GlobeNewswire 03-25 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narc...
GlobeNewswire 03-19 Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depr...
GlobeNewswire 03-05 Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
GlobeNewswire 02-20 Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busines...
GlobeNewswire 01-23 Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
GlobeNewswire 01-04 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anti...
GlobeNewswire 2023-12-11 Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depr...
GlobeNewswire 2023-12-07 Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today